<DOC>
	<DOCNO>NCT02432274</DOCNO>
	<brief_summary>This phase 1/2 study evaluate safety , tolerability , efficacy lenvatinib child adolescent refractory relapse solid malignancy young adult Osteosarcoma .</brief_summary>
	<brief_title>Study Lenvatinib Children Adolescents With Refractory Relapsed Solid Malignancies Young Adults With Osteosarcoma</brief_title>
	<detailed_description>The study consist 5 cohort : Cohort 1 ( Single-Agent Dose-Finding ) use dose-escalation find recommend dose ( RD ) lenvatinib use time-to-event continual reassessment method ( TiTE-CRM ) design child adolescent relapse refractory solid malignant tumor . When RD identify , Cohorts 2A , 2B , 3A start parallel . Cohort 2 ( Single-Agent Expansion ) evaluate efficacy lenvatinib RD child , adolescent , young adult 1 . 131 iodine-refractory differentiate thyroid cancer ( DTC ) [ Cohort 2A ] 2 . Relapsed refractory osteosarcoma [ Cohort 2B ] Cohort 3A ( Combination Dose-Finding ) determine RD lenvatinib combination ifosfamide etoposide participant relapse refractory osteosarcoma . Cohort 3B ( Combination Expansion ) evaluate efficacy lenvatinib RD Cohort 3A combination ifosfamide etoposide participant relapse refractory osteosarcoma . Participants osteosarcoma enrol Cohort 1 2B experienced progressive disease lenvatinib well lenvatinib-naive participant relapse refractory osteosarcoma candidate enrollment Cohort 3B . Lenvatinib provide hard capsule contain 1 , 4 , 10 mg lenvatinib . Lenvatinib capsule dissolved water apple juice child unable swallow capsule .</detailed_description>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis solid malignant tumor . 1 . Cohort 1 : Any solid malignant tumor . 2 . Cohort 2A : Differentiated Thyroid Cancer ( DTC ) one follow histological subtypes : ) Papillary thyroid cancer ( PTC ) . i.a ) Follicular variant . i.b ) Other variant ( include limit tall cell , columnar cell , cribriformmorular , solid , oxyphil , Warthin'slike , trabecular , tumor nodular fasciitislike stroma , Hurthle cell variant papillary carcinoma , poorly differentiate carcinoma ) . ii ) Follicular thyroid cancer ( FTC ) . ii.a ) Hurthle cell . ii.b ) Clear cell . ii.c ) Insular . c ) Cohort 2B , 3A , 3B : Relapsed refractory osteosarcoma . 2 . Relapsed refractory solid tumor malignancy progress standard anticancer therapy available curative option . ( Note : Osteosarcoma participant must first subsequent relapse [ great equal first relapse ] ) . Only osteosarcoma participant enrol Cohorts 3A 3B must deem candidate ifosfamide etoposide chemotherapy ) . 3 . Evaluable measurable disease meet follow criterion : 1 . Participants must evaluable measurable disease base RECIST 1.1 use compute tomography ( CT ) /magnetic resonance imaging ( MRI ) . 2 . Lesions external beam radiotherapy ( EBRT ) locoregional therapy radiofrequency ( RF ) ablation must subsequently grow unequivocally deem target lesion . 4 . DTC participant must 131 iodinerefractory/ relapse define least one following : 1 . One evaluable measurable lesion demonstrate iodine uptake radioiodine scan ; 2 . One evaluable measurable lesion progress base RECIST 1.1 , within 12 month 131 iodine therapy , despite demonstration radioiodine avidity time treatment pre posttreatment scan . These participant must eligible possible curative surgery ; 3 . Cumulative activity 131 iodine great 400 millicurie ( mCi ) 14.8 gigabecquerels ( GBq ) , last dose administer least 6 month prior study entry . 5 . Participants DTC must receive thyroxine suppression therapy level thyroid stimulate hormone ( TSH ) elevate ( TSH le equal 5.50 milliunits per liter ( mU/L ) ) . When tolerated participant , thyroxine dose change achieve TSH suppression ( TSH le 0.50 mU/L ) . 6 . Participants known central nervous system ( CNS ) primary tumor metastasis complete brain therapy ( radiotherapy , stereotactic radiosurgery , surgical resection ) remain clinically stable , asymptomatic , steroid 2 week prior Cycle 1 Day 1 eligible . 7 . Male female participant age 2 year less than18 year less equal 25 year osteosarcoma subject time inform consent . 8 . Lansky play score great equal 50 % Karnofsky Performance Status score great equal 50 % . Use Karnofsky participant great equal 16 year age Lansky participant less 16 year age . 9 . Life expectancy great equal 3 month . 10 . Adequate bone marrow function evidence : 1. absolute neutrophil count ( ANC ) great equal 1.0 x 10^9/L ( Cohorts 3A 3B leucocyte count great equal 2 x 10^9/L ; participant bone marrow involvement ANC great equal 0.8 x 10^9/L leucocyte count great equal 1 x 10^9/L ) . 2. hemoglobin great equal 8.0 grams/deciliter ( g/dL ) ( hemoglobin less 8.0 g/dL acceptable correct growth factor transfusion start lenvatinib ) . 3. platelet count great equal 75 x 10^9/L . 11 . Adequate liver function evidence : 1. bilirubin less equal 1.5 time upper limit normal ( ULN ) . 2. alkaline phosphatase , alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) less equal 3 time ULN . 12 . Adequate renal function evidence : ) Serum creatinine base age/gender . If serum creatinine great maximum serum creatinine age/gender show table , creatinine clearance ( radioisotope glomerular filtration rate [ GFR ] ) must great 70 milliliter/minute/1.73 square meter ( mL/min/1.73 m2 ) . Maximum Serum Creatinine milligrams/deciliter ( mg/dL ) male : . Age 2 le 6 year = 0.8 ii . Age 6 le 10 year = 1.0 iii . Age 10 le 13 year = 1.2 iv . Age 13 le 16 year = 1.5 v. Age great equal 16 year = 1.7 Maximum Serum Creatinine ( mg/dL ) Female : vi . Age 2 le 6 year = 0.8 vii . Age 6 le 10 year = 1.0 viii . Age 10 le 13 year = 1.2 ix . Age 13 le 16 year = 1.4 x . Age great equal 16 year = 1.4 The threshold creatinine value Table derive Schwartz formula estimate glomerular filtration rate use child length stature data publish CDC . b ) Urine dipstick le 2+ proteinuria . Participants great equal 2+ proteinuria dipstick urinalysis undergo spot proteincreatinine ( P/C ) ratio Grade le 2. c ) No clinical evidence nephrotic syndrome . 13 . Adequate cardiac function evidence leave ventricular ejection fraction ( LVEF ) great equal 50 % ) baseline determine echocardiography . 14 . Adequately control blood pressure ( BP ) without antihypertensive medication , define : BP le 95th percentile sex , age , height/length screening ( per National Heart Lung Blood Institute guideline ) change antihypertensive medication within 1week prior Cycle 1/Day 1 . Osteosarcoma subject 18 25 year BP ≤150/90 mm Hg screen change antihypertensive therapy within 1 week prior Cycle 1/Day 1 . 15 . Washout 3 week case prior chemotherapy , 6 week treatment include nitrosoureas ; 4 week definitive radiotherapy , 2 week palliative radiotherapy ; 3 month highdose chemotherapy stem cell rescue ; 3 week major surgery . Participants must recover acute toxic effect prior anticancer therapy enrollment study . 16 . Written sign inform consent parent ( ) legal representative ( guardian ) assent minor participant . Written inform consent subject ≥18 year . 17 . Willing able comply protocol , schedule followup , management toxicity judge Investigator . Cohort 3B ( Combination Expansion ) : Osteosarcoma subject progress Cohorts 1 2B opt receive combination therapy . 18 . Osteosarcoma participant receive combination therapy lenvatinib ifosfamide etoposide meet Inclusion Criteria Numbers 6 17 ( progression Cohort 2B ) . Exclusion criterion : 1 . Any active infection infectious illness unless fully recover prior dose . 2 . Any medical condition opinion investigator ( ) would preclude participant 's participation clinical study . 3 . Other organ toxicity due prior anticancer therapy ( investigational agent , chemotherapy , radiation therapy ) except alopecia , ototoxicity due cisplatin already cover inclusion/exclusion criterion , recover Grade le 2 per Common Terminology Criteria Adverse Events ( CTCAE ) v4.0 . 4 . Known hypersensitivity component product ( lenvatinib ingredient ) . 5 . Concurrent administration antitumor therapy . 6 . Previous treatment lenvatinib ( except participant previously enrol Cohorts 1 2B study ) . 7 . Two prior vascular endothelial growth factor/vascular endothelial growth factor receptor ( VEGF/VEGFR ) target therapy . 8 . Currently receive investigational drug device another clinical trial within 30 day precede informed consent . 9 . A clinically significant ECG abnormality , include mark baseline prolong QT QTc interval ( eg , repeated demonstration QTc interval great 480 msec ) . 10 . Gastrointestinal malabsorption condition opinion investigator might affect absorption lenvatinib . 11 . Gastrointestinal bleed active hemoptysis ( bright red blood least half teaspoon ) within 3 week prior first dose study drug . 12 . Active second malignancy within 2 year prior enrollment ( [ addition primary tumor type specify cohort Inclusion Criterion Number 1 ] , include definitively treat superficial melanoma , insitu , basal squamous cell carcinoma skin ) . 13 . Previous treatment ifosfamide Grade great equal 3 nephrotoxicity encephalopathy ( Cohorts 3A 3B ) . 14 . Females breastfeed pregnant Screening Baseline ( document positive betahuman chorionic gonadotropin [ ßhCG ] ( human chorionic gonadotropin [ hCG ] ) test minimum sensitivity 25 IU/L equivalent unit ßhCG [ hCG ] ) . A separate baseline assessment require negative screening pregnancy test obtain 72 hour first dose study drug . Cohort 3B ( Combination Expansion ) : Osteosarcoma participant progress Cohorts 1 2B opt receive combination therapy . 15 . Osteosarcoma participant receive combination therapy lenvatinib ifosfamide etoposide meet exclusion criterion , exception Criterion Number 6 .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>E7080</keyword>
	<keyword>Lenvatinib</keyword>
	<keyword>Solid malignancy</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Differentiated Thyroid Cancer</keyword>
</DOC>